FDA ▶ Regulatory submissions

CardiAMP™ Cell Therapy for Heart Failure Trial (2016)

  Back

https://uploads-ssl.webflow.com/65dc93ef0a9b2f3705d0635e/6602a1ab1502e49bec5c7d24_BC%20Logo%20Transparent.jpg

https://clinicaltrials.gov/study/NCT02438306

Read also



Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (2019)
FDA
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (2019)
READ MORE →
 Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery (2023)
FDA
Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery (2023)
READ MORE →
 Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (2019)
FDA
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (2019)
READ MORE →
 Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (2019)
FDA
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (2019)
READ MORE →